TD Cowen analyst Tara Bancroft raised the firm’s price target on Vaxcyte (PCVX) to $75 from $50 and keeps a Buy rating on the shares. The firm said Vaxcyte enters 2026 with a largely de-risked path for VAX-31, supported by differentiated Phase II data and a comprehensive Phase III OPUS program targeting BLA filing in 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCVX: